Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 10/20 | 0.45 |
| ▸ | CASP9 | P55211 | 1/20 | 0.45 |
| ▸ | BIRC2 | Q13490 | 11/20 | 0.45 |
| ▸ | BIRC3 | Q13489 | 8/20 | 0.45 |
| ▸ | BIRC7 | Q96CA5 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13104636 | 0.94 | XIAP (0.53) | XIAPCASP9BIRC2BIRC3BIRC7 | |
| SCHEMBL10066058 | 0.92 | XIAP (0.46) | XIAPCASP9BIRC2BIRC3BIRC7 | |
| SCHEMBL13104648 | 0.85 | XIAP (0.54) | XIAPCASP9BIRC2BIRC3BIRC7 | |
| SCHEMBL10066051 | 0.85 | XIAP (0.47) | XIAPBIRC2BIRC3BIRC7LMNA | |
| SCHEMBL10066061 | 0.85 | XIAP (0.46) | XIAPCASP9BIRC2BIRC3BIRC7 | |
| SCHEMBL10066066 | 0.83 | XIAP (0.60) | XIAPBIRC2BIRC3BIRC7 | |
| SCHEMBL13104651 | 0.82 | XIAP (0.47) | XIAPCASP9BIRC2BIRC3BIRC7 | |
| SCHEMBL10066055 | 0.81 | XIAP (0.43) | XIAPCASP9BIRC2BIRC3BIRC7 | |
| SCHEMBL10066056 | 0.81 | XIAP (0.48) | XIAPBIRC2BIRC3BIRC7LMNA | |
| SCHEMBL896286 | 0.81 | XIAP (0.43) | XIAPCASP9BIRC2BIRC3BIRC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281385-A1 | SMALL MOLECULE APOPTOSIS PROMOTERS | JOYANT PHARMACEUTICALS, INC. | 2013-10-24 | — | — | US | disclosed |
| US-8222291-B2 | Small molecule apoptosis promoters | JOYANT PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20120082640-A1 | Small molecule apoptosis promoters | JOYANT PHARMACEUTICALS, INC. | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281385-A1 | SMALL MOLECULE APOPTOSIS PROMOTERS | BID, BAD, BAX | XIAP 31/4885CASP9 30/4885BIRC2 11/4885 |
| US-20120082640-A1 | Small molecule apoptosis promoters | BID, BAD, BAX | XIAP 31/4885CASP9 30/4885BIRC2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.